TVTX ▲ +3.0% - Travere Therapeutics, Inc. $TVTX Canaccord analyst Edward Nash raised the firm's price target on Travere Therapeutics to $72 from $70 and keeps a Buy rating on the shares. The firm updated its model following Q3 results where they reported higher-than-expected Filspari revenue, at $200.2M compared to consensus estimate of $170.3M. Diluted EPS came in lower than consensus expectations at -$0.55 compared to -$0.10. 04-NOV-2026 07:41 AM ET